These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28610791)

  • 1. The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs.
    Bax HI; Bakker-Woudenberg IAJM; de Vogel CP; van der Meijden A; Verbon A; de Steenwinkel JEM
    Tuberculosis (Edinb); 2017 Jul; 105():80-85. PubMed ID: 28610791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis.
    Maltempe FG; Caleffi-Ferracioli KR; do Amaral RCR; de Oliveira Demitto F; Siqueira VLD; de Lima Scodro RB; Hirata MH; Pavan FR; Cardoso RF
    Tuberculosis (Edinb); 2017 May; 104():24-29. PubMed ID: 28454646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.
    de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE
    Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro combinatory activity of piperine and anti-tuberculosis drugs in Mycobacterium tuberculosis.
    Hegeto LA; Caleffi-Ferracioli KR; Nakamura-Vasconcelos SS; Almeida AL; Baldin VP; Nakamura CV; Siqueira VLD; Scodro RBL; Cardoso RF
    Tuberculosis (Edinb); 2018 Jul; 111():35-40. PubMed ID: 30029912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colistin as a potentiator of anti-TB drug activity against Mycobacterium tuberculosis.
    Bax HI; de Steenwinkel JE; Ten Kate MT; van der Meijden A; Verbon A; Bakker-Woudenberg IA
    J Antimicrob Chemother; 2015 Oct; 70(10):2828-37. PubMed ID: 26183185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of killing kinetics of anti-tuberculosis drugs on Mycobacterium tuberculosis using a bacteriophage-based assay.
    Marcel N; Nahta A; Balganesh M
    Chemotherapy; 2008; 54(5):404-11. PubMed ID: 18772589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fast detection of drug interaction in Mycobacterium tuberculosis by a checkerboard resazurin method.
    Caleffi-Ferracioli KR; Maltempe FG; Siqueira VL; Cardoso RF
    Tuberculosis (Edinb); 2013 Nov; 93(6):660-3. PubMed ID: 24083948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis.
    de Steenwinkel JE; de Knegt GJ; ten Kate MT; van Belkum A; Verbrugh HA; Kremer K; van Soolingen D; Bakker-Woudenberg IA
    J Antimicrob Chemother; 2010 Dec; 65(12):2582-9. PubMed ID: 20947621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.
    Rani C; Mehra R; Sharma R; Chib R; Wazir P; Nargotra A; Khan IA
    Tuberculosis (Edinb); 2015 Dec; 95(6):664-677. PubMed ID: 26318557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.
    Gumbo T; Louie A; Liu W; Ambrose PG; Bhavnani SM; Brown D; Drusano GL
    J Infect Dis; 2007 Jan; 195(2):194-201. PubMed ID: 17191164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis.
    Machado D; Pires D; Perdigão J; Couto I; Portugal I; Martins M; Amaral L; Anes E; Viveiros M
    PLoS One; 2016; 11(2):e0149326. PubMed ID: 26919135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effect of two combinations of antituberculous drugs against Mycobacterium tuberculosis.
    Rey-Jurado E; Tudó G; Martínez JA; González-Martín J
    Tuberculosis (Edinb); 2012 May; 92(3):260-3. PubMed ID: 22342247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.
    Hartkoorn RC; Chandler B; Owen A; Ward SA; Bertel Squire S; Back DJ; Khoo SH
    Tuberculosis (Edinb); 2007 May; 87(3):248-55. PubMed ID: 17258938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-resistance of Mycobacterium tuberculosis in Patras, Greece.
    Trakada G; Tsiamita M; Spiropoulos K
    Monaldi Arch Chest Dis; 2004; 61(1):65-70. PubMed ID: 15366340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-TB drug resistance levels and patterns among Mycobacterium tuberculosis isolated from newly diagnosed cases of pulmonary tuberculosis in Dar es Salaam, Tanzania.
    Matee M; Mfinanga S; Holm-Hansen C
    APMIS; 2009 Apr; 117(4):263-7. PubMed ID: 19338514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.
    Gumbo T; Louie A; Liu W; Brown D; Ambrose PG; Bhavnani SM; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2329-36. PubMed ID: 17438043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the Combined Antibacterial Effect of Isoniazid and Rifampin on Four Mycobacterium tuberculosis Strains Using
    Genestet C; Ader F; Pichat C; Lina G; Dumitrescu O; Goutelle S
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycobacterium tuberculosis Uganda II is more susceptible to rifampicin and isoniazid compared to Beijing and Delhi/CAS families.
    Kasule GW; Kateete DP; Joloba ML
    BMC Infect Dis; 2016 Apr; 16():173. PubMed ID: 27097724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter evaluation of the nitrate reductase assay for drug resistance detection of Mycobacterium tuberculosis.
    Martin A; Montoro E; Lemus D; Simboli N; Morcillo N; Velasco M; Chauca J; Barrera L; Ritacco V; Portaels F; Palomino JC
    J Microbiol Methods; 2005 Nov; 63(2):145-50. PubMed ID: 15893391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.